IRIS
MINARI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.845
AS - Asia 2.653
EU - Europa 1.855
SA - Sud America 367
AF - Africa 168
OC - Oceania 3
Totale 7.891
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.781
SG - Singapore 903
IT - Italia 672
CN - Cina 591
VN - Vietnam 504
BR - Brasile 267
HK - Hong Kong 225
IE - Irlanda 216
SE - Svezia 173
DE - Germania 169
FR - Francia 114
ZA - Sudafrica 100
NL - Olanda 97
RU - Federazione Russa 90
IN - India 88
GB - Regno Unito 80
AT - Austria 56
FI - Finlandia 52
BD - Bangladesh 49
AR - Argentina 40
TR - Turchia 35
CA - Canada 33
JP - Giappone 31
KR - Corea 31
PH - Filippine 27
ES - Italia 26
ID - Indonesia 26
CI - Costa d'Avorio 24
PK - Pakistan 22
CZ - Repubblica Ceca 21
IQ - Iraq 20
PL - Polonia 19
MX - Messico 18
CO - Colombia 15
UZ - Uzbekistan 15
EC - Ecuador 14
UA - Ucraina 13
IR - Iran 12
BE - Belgio 11
MA - Marocco 10
VE - Venezuela 10
JO - Giordania 8
LT - Lituania 8
SA - Arabia Saudita 8
TN - Tunisia 8
TW - Taiwan 8
EG - Egitto 7
LU - Lussemburgo 7
PY - Paraguay 7
CL - Cile 6
KZ - Kazakistan 6
MY - Malesia 6
TH - Thailandia 6
BG - Bulgaria 4
IL - Israele 4
NP - Nepal 4
RO - Romania 4
SN - Senegal 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
DK - Danimarca 3
KE - Kenya 3
LB - Libano 3
MK - Macedonia 3
PE - Perù 3
PS - Palestinian Territory 3
BO - Bolivia 2
BW - Botswana 2
CG - Congo 2
ET - Etiopia 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
JM - Giamaica 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
SV - El Salvador 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
LK - Sri Lanka 1
Totale 7.882
Salva come PNG Salva come JPEG
Città #
Singapore 534
Ashburn 501
Dallas 443
San Jose 242
Dublin 210
Hong Kong 209
Chandler 200
Parma 173
Santa Clara 161
Ho Chi Minh City 152
Hanoi 122
Boardman 119
Beijing 114
Johannesburg 93
Munich 90
Milan 88
Los Angeles 86
Ann Arbor 84
Shanghai 79
Hefei 76
New York 63
Lauterbourg 55
Chicago 45
Vienna 44
Bologna 43
Council Bluffs 37
Moscow 34
Marseille 29
São Paulo 28
Verona 27
Buffalo 26
Da Nang 25
Abidjan 24
London 23
Princeton 22
Seoul 22
Tokyo 22
Frankfurt am Main 21
Atlanta 19
Nuremberg 19
Denver 18
Helsinki 18
Turku 17
Dearborn 16
The Dalles 16
Warsaw 16
West Jordan 16
Amsterdam 15
Jakarta 15
Rome 15
Bengaluru 14
Bremen 14
Columbus 14
Haiphong 14
Brno 13
Modena 13
Chennai 12
Rio de Janeiro 12
Stockholm 12
Brussels 11
Izmir 11
Lahore 11
Montreal 11
Pune 11
Brescia 10
Des Moines 10
Houston 10
Istanbul 10
Manchester 10
Orem 10
Poplar 10
Tashkent 10
Wilmington 10
Buenos Aires 9
Redondo Beach 9
Seattle 9
Toronto 9
Amman 8
Belo Horizonte 8
Biên Hòa 8
Chongqing 8
Düsseldorf 8
Nanjing 8
Phoenix 8
Brasília 7
Changsha 7
Fremont 7
Jinan 7
Kolkata 7
Pavia 7
Ravenna 7
Shenyang 7
Auburn 6
Brooklyn 6
Busseto 6
Cascina 6
Dhaka 6
Florence 6
Kyiv 6
Olomouc 6
Totale 5.025
Salva come PNG Salva come JPEG
Nome #
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 239
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 214
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 210
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 204
227P Sexual dimorphism in immune profile of early and advanced NSCLC 198
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 198
Evidence fo Epigenetic Abnormalities of the Androgen Receptor Gene in Foreskin from Children with Hypospadias 191
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 189
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 175
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 174
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 170
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 164
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 161
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 160
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 160
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 155
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 152
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 151
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 147
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 145
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 144
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
A novel mutation in the nr0b1 gene in a family with monozygotic twin sisters and congenital adrenal hypoplasia affected children. 144
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 144
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 140
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 138
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 133
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 130
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 127
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 126
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 125
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 124
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 123
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 120
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 118
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 116
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 112
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 109
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 107
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 106
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 104
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 97
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 97
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 92
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 91
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 89
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 89
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 87
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 85
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 85
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 76
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 75
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 67
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 62
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 56
Totale 7.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.356
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202137 0 0 0 0 0 0 0 0 0 8 14 15
2021/2022215 19 8 10 16 11 2 43 10 17 3 20 56
2022/2023849 67 84 37 73 83 87 15 64 242 7 61 29
2023/2024656 30 24 15 28 58 89 62 35 36 70 86 123
2024/20251.895 101 105 144 152 165 146 151 108 170 165 164 324
2025/20264.068 376 372 692 419 470 236 414 190 607 292 0 0
Totale 7.996